Cargando…

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

BACKGROUND: Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD). METHODS: In this study, we evaluated DPYD promoter methylation through quantitative methy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savva-Bordalo, Joana, Ramalho-Carvalho, João, Pinheiro, Manuela, Costa, Vera L, Rodrigues, Ângelo, Dias, Paula C, Veiga, Isabel, Machado, Manuela, Teixeira, Manuel R, Henrique, Rui, Jerónimo, Carmen
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940808/ https://www.ncbi.nlm.nih.gov/pubmed/20809970 http://dx.doi.org/10.1186/1471-2407-10-470

Ejemplares similares

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
por: Wigle, Theodore J., et al.
Publicado: (2019)

Intragenic β-synuclein rearrangements in malignancy
por: Xiao, Peifang, et al.
Publicado: (2023)

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil
por: Winquist, Lauren E., et al.
Publicado: (2020)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
por: Amstutz, Ursula, et al.
Publicado: (2008)

Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Li, Qiang, et al.
Publicado: (2014)

Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Research and Practice, Gastroenterology
Publicado: (2020)

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
por: De Luca, Ottavia, et al.
Publicado: (2022)

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant
por: Majounie, Elisa, et al.
Publicado: (2020)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants
por: Wegert, Jenny, et al.
Publicado: (2018)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

A complex intragenic rearrangement of ERCC8 in Chinese siblings with Cockayne syndrome
por: Xie, Hua, et al.
Publicado: (2017)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion
por: Silva, Amanda Gonçalves, et al.
Publicado: (2012)

Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle-eye-brain disease
por: Saredi, S., et al.
Publicado: (2012)

Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations
por: Ramalho-Carvalho, João, et al.
Publicado: (2013)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
por: Lau, David K., et al.
Publicado: (2023)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016)

High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic
por: Vasickova, Petra, et al.
Publicado: (2007)

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements
por: Schieffer, Kathleen M., et al.
Publicado: (2023)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Ridge, S. A., et al.
Publicado: (1997)

Mutations at codon 974 of the DPYD gene are a rare event.
por: Diasio, R. B., et al.
Publicado: (1997)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
por: White, Cassandra, et al.
Publicado: (2021)

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
por: van Kuilenburg, André B. P., et al.
Publicado: (2010)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity
por: Hamzic, Seid, et al.
Publicado: (2021)

Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements
por: Santos, Joana, et al.
Publicado: (2015)

Langerhans cell histiocytosis involving the liver of a male smoker: a case report
por: Savva-Bordalo, Joana, et al.
Publicado: (2008)

Impact of DPYD, DPYS, and UPB1 gene variations on severe drug‐related toxicity in patients with cancer
por: Yokoi, Katsuyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rnmneb94opvvblfn8204nkg2vf